Efficacy of Omalizumab in Indolent Systemic Mastocytosis
Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficac...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2019/3787586 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561992932524032 |
|---|---|
| author | Calum Slapnicar Martina Trinkaus Lisa Hicks Peter Vadas |
| author_facet | Calum Slapnicar Martina Trinkaus Lisa Hicks Peter Vadas |
| author_sort | Calum Slapnicar |
| collection | DOAJ |
| description | Background. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited. Methods. A retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St. Michael’s Hospital between 2009 and 2018 is described. Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease. Results. Of the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions. Significant improvement in cutaneous symptoms was also observed. Conclusion. These data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies. |
| format | Article |
| id | doaj-art-915b2fac541d4ef3878b62ab0516458c |
| institution | Kabale University |
| issn | 2090-6560 2090-6579 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-915b2fac541d4ef3878b62ab0516458c2025-02-03T01:23:45ZengWileyCase Reports in Hematology2090-65602090-65792019-01-01201910.1155/2019/37875863787586Efficacy of Omalizumab in Indolent Systemic MastocytosisCalum Slapnicar0Martina Trinkaus1Lisa Hicks2Peter Vadas3Division of Allergy and Clinical Immunology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaDivision of Hematology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaDivision of Hematology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaDivision of Allergy and Clinical Immunology, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, CanadaBackground. Systemic mastocytosis (SM) comprises a heterogeneous group of disorders characterized by the proliferation of clonal mast cells in skin and various internal organs. Omalizumab is an established, labelled therapy for allergic asthma and chronic urticaria, but its experience in the efficacy of SM is limited. Methods. A retrospective analysis of 6 patients diagnosed with indolent SM treated with omalizumab at St. Michael’s Hospital between 2009 and 2018 is described. Reported frequency of anaphylaxis, baseline and follow-up tryptase levels, and SM-related symptoms were captured to measure the control of the disease. Results. Of the 5 patients who had experienced unprovoked anaphylaxis prior to treatment with omalizumab, 3 had no further episodes of anaphylaxis following initiation of omalizumab, while the remaining 2 patients had milder multisystem reactions. Significant improvement in cutaneous symptoms was also observed. Conclusion. These data suggest that omalizumab provides benefit to patients with SM who remain highly symptomatic in spite of treatment with conventional therapies.http://dx.doi.org/10.1155/2019/3787586 |
| spellingShingle | Calum Slapnicar Martina Trinkaus Lisa Hicks Peter Vadas Efficacy of Omalizumab in Indolent Systemic Mastocytosis Case Reports in Hematology |
| title | Efficacy of Omalizumab in Indolent Systemic Mastocytosis |
| title_full | Efficacy of Omalizumab in Indolent Systemic Mastocytosis |
| title_fullStr | Efficacy of Omalizumab in Indolent Systemic Mastocytosis |
| title_full_unstemmed | Efficacy of Omalizumab in Indolent Systemic Mastocytosis |
| title_short | Efficacy of Omalizumab in Indolent Systemic Mastocytosis |
| title_sort | efficacy of omalizumab in indolent systemic mastocytosis |
| url | http://dx.doi.org/10.1155/2019/3787586 |
| work_keys_str_mv | AT calumslapnicar efficacyofomalizumabinindolentsystemicmastocytosis AT martinatrinkaus efficacyofomalizumabinindolentsystemicmastocytosis AT lisahicks efficacyofomalizumabinindolentsystemicmastocytosis AT petervadas efficacyofomalizumabinindolentsystemicmastocytosis |